Abstract: Objective： To investigate the effect of linezolid on serum CRP and TNF-α levels， and to analyze its clinical curative effect for MRSA pneumonia patients. Methods： 62 patients with MRSA pneumonia were divided into 2 groups， 32 cases (treated with linezolid)in the experimental group， and 30 cases（treated with vancomycin） in the control group in our hospital from April 2013 to March 2015. Serum CRP and TNF-α levels were compared between 2 groups before and after drug treatment， and the efficacy and adverse reaction of linezolid and vancomycin were observed. 32 strains of MRSA isolated from the experimental group were induced in vitro， and then the changes of the drug resistance were observed. Results： The effective rate in the experimental group (87.5%) was significantly higher than the control group (60.0%)， P<0.05. Serum CRP and TNF-α levels were significantly decreased in 2 groups after treatment， P < 0.05. And serum CRP and TNF-α levels in the experimental group were also significantly decreased than the control group， P<0.05. The therapeutic effects were evaluated by detecting the changes of serum CRP and TNF-α levels， and the sensitivity was 93.5% (58/62). The bacterial clearance rate in the experimental group (78.1%) was significantly higher than the control group(50.0%) after treatment， P<0.05，but there was no significant difference of adverse reaction rate between 2 groups. The minimum inhibitory concentration(MIC) of linezolid on MRSA changed little after 21 times induce in vitro， and the MIC value was 4 mg?L-1. Conclusion： Linezolid could significantly reduce the serum CRP and TNF-α levels in MRSA pneumonia patients， and the therapeutic effects were evaluated by detecting the changes of serum CRP and TNF-α levels. Linezolid was safe and effective， and linezolid hardly induced MRSA resistant against drug. Linezolid should be worthy of promotion and application in clinical with excellent characteristics.